What is 180 Life Sciences Debt-to-Equity?
180 Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.77 Mil. 180 Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.02 Mil. 180 Life Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-0.95 Mil.
180 Life Sciences's debt to equity for the quarter that ended in Mar. 2024 was -0.83.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for 180 Life Sciences's Debt-to-Equity or its related term are showing as below:
ATNF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -8.23 Med: 0.05 Max: 0.6
Current: -0.83
During the past 5 years, the highest Debt-to-Equity Ratio of 180 Life Sciences was 0.60. The lowest was -8.23. And the median was 0.05.
180 Life Sciences Debt-to-Equity Historical Data
The historical data trend for 180 Life Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
180 Life Sciences Debt-to-Equity Chart
|
180 Life Sciences Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
0.09 |
0.13 |
0.05 |
0.12 |
-8.23 |
|
180 Life Sciences Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.12 |
0.09 |
-2.38 |
-8.23 |
-0.83 |
Competitive Comparison of 180 Life Sciences's Debt-to-Equity
For the Biotechnology subindustry, 180 Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
180 Life Sciences's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 180 Life Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where 180 Life Sciences's Debt-to-Equity falls into.
180 Life Sciences Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
180 Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
180 Life Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
180 Life Sciences (180 Life Sciences) Business Description
Traded in Other Exchanges
N/A
Address
3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.
Executives
| James N. Woody |
director, officer: Chief Executive Officer |
C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
| Marc Feldmann |
director |
5 DURHAM TERRACE, LONDON X0 W25PB |
| Lawrence Steinman |
director |
10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
| Mcgovern Jr. Donald A. |
director |
C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606 |
| Quan Anh Vu |
officer: COO / Chief Business Officer |
22616 ERWIN STREET, WOODLAND HILLS CA 91367 |
| Ozan Pamir |
officer: Interim CFO |
2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115 |
| Pamela G Marrone |
director |
C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618 |
| Teresa Deluca |
director |
40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215 |
| Russell T Ray |
director |
2525 DUPONT DR, IRVINE CA 92612 |
| Knuettel Ii Francis |
director |
205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701 |
| Marlene Krauss |
director, 10 percent owner, officer: Chief Executive Officer |
C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022 |
| Lawrence Marshall Gold |
director |
830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025 |
| Jonathan B. Rothbard |
officer: Chief Scientific Officer |
501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105 |
| Shoshana Shendelman |
director |
C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
| Richard W Barker |
director |
290 COMMONWEALTH AVENUE #17, BOSTON MA 02115 |
180 Life Sciences (180 Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATNF has been successfully added to your